Aclaris Therapeutics (ACRS) Announces Proposed Public Offering of Common Stock

Aclaris Therapeutics (ACRS) Prices 5.48M Share Common Stock Offering at $17.50/sh

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share. In... More

Aclaris Therapeutics (ACRS) Climbs 70% Following Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for RA

Aclaris Therapeutics (NASDAQ: ACRS) Climbs 70% Following Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for RA

Aclaris Therapeutis (ACRS) PT Raised to $15 at Cantor Fitzgerald; 'Data That Support Potential 1L, First-in-Class, Best-In-Class Drug for RA'

Cantor Fitzgerald analyst Louise Chen raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $15.00 (from $7.00) while maintaining an Overweight rating.

The analyst commented, "Today (1/19), ACRS announced positive Phase 2a data for ATI-450 (MK2 inhibitor) to treat moderate to severe RA. The data... More

Aclaris Therapeutics (ACRS) Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris proprietary KINect drug discovery platform.

In the trial, 19 subjects were randomized in a 3:1 ratio and received either ATI-450 at 50 mg twice... More